Inflammatory Myofibroblastic Tumor Showing Durable Remission after Anthracycline-Containing Cytotoxic Chemotherapy: Report of a Case / 대한내과학회지
Korean Journal of Medicine
;
: 749-753, 2012.
Artículo
en Coreano
| WPRIM
| ID: wpr-741103
ABSTRACT
An inflammatory myofibroblastic tumor (IMT) is a rare disease entity, and the clinical characteristics range from indolent to aggressive forms. No established management for patients with unresectable or aggressive IMT is available. We report on a 62-year-old patient with aggressive IMT who achieved a durable partial response lasting 12 months after anthracycline-containing cytotoxic chemotherapy without corticosteroids. The patient was admitted for an evaluation of progressive weight loss and lower abdominal pain lasting for 2 weeks. Abdominopelvic computed tomography revealed a 10 cm sized heterogeneous mass in the mesentery that encased the superior mesenteric artery and a liver metastasis. The diagnosis of IMT was confirmed by percutaneous core needle biopsy of the mesenteric mass. Systemic chemotherapy was performed after confirming disease progression during a 1 month observation period. A partial response was obtained after two cycles of chemotherapy. Anthracycline-containing cytotoxic chemotherapy could be a treatment option for patients with aggressive IMT.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piperidonas
/
Pérdida de Peso
/
Dolor Abdominal
/
Arteria Mesentérica Superior
/
Corticoesteroides
/
Progresión de la Enfermedad
/
Enfermedades Raras
/
Bencenoacetamidas
/
Miofibroblastos
/
Biopsia con Aguja Gruesa
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2012
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS